



October 28, 2019

Whom It May Concern

Company: KYORIN Holdings, Inc.  
Representative: Yutaka Ogihara  
Representative Director, President  
(Security Code: 4569, TSE 1st Sec.)  
Contact: Yoshinori Tanifuji  
Director, Management Strategy &  
Planning Division Corporate Planning  
Telephone: 03-3525-4707

### **Resumption of Supply of Desalex® Tablets 5mg Long-Acting Selective H1 Receptor Antagonist for Allergic Diseases Treatment**

KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Minoru Hogawa, "KYORIN Pharmaceutical"), which is a subsidiary of KYORIN Holdings, Inc., previously announced that MSD K.K. (Head office: Chiyoda-ku, Tokyo, President & CEO: Jannie Oosthuizen, "MSD") had decided to voluntarily recall (Class II) Desalex® Tablets 5mg (the "Product") after some procedural flaw was found in a storage facility of MSD for the active pharmaceutical ingredient and that the Product would not be available for a certain period starting from January 7, 2019. MSD is the marketing approval holder for Desalex® Tablets 5mg, which are being distributed by KYORIN Pharmaceutical. The Company offers its sincere apologies to patients and healthcare professionals for the anxiety and inconvenience this incident has caused.

MSD has consistently done its utmost to resume supply of the Product following the suspension of supply, including completing regulatory procedures such as the partial amendment of marketing approval and ensuring the level of inventory considered necessary for stable supply. MSD is now ready to resume supply of the Product and it is currently estimated that November 18, 2019 will be the date that KYORIN Pharmaceutical resumes supply of the Product to the market. The Company once again apologizes for the lengthy suspension in the supply of this product. KYORIN Pharmaceutical remains committed to the pharmaceutical companies' mission of the stable supply of medicinal products to medical settings.

#### [Product Outline]

Generic Name: Desloratadine

Trade Name: Desalex® Tablets 5mg

Indications: Allergic rhinitis, urticaria and skin diseases (eczema, dermatitis, skin pruritus)

Companies: Distributor KYORIN Pharmaceutical Co., Ltd. Promotion Partner Kaken  
Pharmaceutical Co., Ltd. Marketing Approval Holder MSD K.K.

#### [Impact on the Company's Financial Performance]

Revenue resulting from resumption of supply of the Product has already been factored into the Consolidated Results Forecast for the Fiscal Year Ending March 31, 2020, which we announced on May 13, 2019. Any revisions that become necessary in the future will be announced promptly.